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Abstract
Background: Alcohol consumption is a known risk factor for liver disease in HIV-infected populations. Therefore,
knowledge of alcohol consumption behaviour and risk of disease progression associated with hazardous drinking
are important in the overall management of HIV disease. We aimed at assessing the usefulness of routine data
collected on alcohol consumption in predicting risk of severe liver disease (SLD) among people living with HIV
(PLWHIV) with or without hepatitis C infection seen for routine clinical care in Italy.
Methods: We included PLWHIV from two observational cohorts in Italy (ICONA and HepaICONA). Alcohol
consumption was assessed by physician interview and categorized according to the National Institute for Food and
Nutrition Italian guidelines into four categories: abstainer; moderate; hazardous and unknown. SLD was defined as
presence of FIB4 > 3.25 or a clinical diagnosis of liver disease or liver-related death. Cox regression analysis was used
to evaluate the association between level of alcohol consumption at baseline and risk of SLD.
Results: Among 9542 included PLWHIV the distribution of alcohol consumption categories was: abstainers 3422
(36%), moderate drinkers 2279 (23%), hazardous drinkers 637 (7%) and unknown 3204 (34%). Compared to
moderate drinkers, hazardous drinking was associated with higher risk of SLD (adjusted hazard ratio, aHR = 1.45;
95% CI: 1.03–2.03). After additionally controlling for mode of HIV transmission, HCV infection and smoking, the
association was attenuated (aHR = 1.32; 95% CI: 0.94–1.85). There was no evidence that the association was stronger
when restricting to the HIV/HCV co-infected population.
Conclusions: Using a brief physician interview, we found evidence for an association between hazardous alcohol
consumption and subsequent risk of SLD among PLWHIV, but this was not independent of HIV mode of
transmission, HCV-infection and smoking. More efforts should be made to improve quality and validity of data on
alcohol consumption in cohorts of HIV/HCV-infected individuals.
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Background
Identifying unhealthy levels of alcohol consumption in
HIV patients seen for routine clinical care is important
because of the possible role alcohol plays in HIV disease
progression as well as non HIV-related comorbidities such
as liver failure [1]. In the era of combination antiretroviral
treatment (cART), people living with HIV/AIDS
(PLWHIV) are now living longer and long term effects of
alcohol consumption are likely to affect people’s quality of
life and survival [2]. Therefore, knowledge of alcohol con-
sumption behaviour and risk of disease progression asso-
ciated with hazardous drinking are important in the
overall management of HIV disease [3]. Alcohol con-
sumption is common in PLWHIV with estimates of
current alcohol use reported to be 50% in studies of HIV-
positive people [1, 4–8] and hazardous drinking, has re-
ported prevalence ranging between 8 and 12%. Hazardous
drinking can lead to harmful consequences such as liver
disease progression or liver related mortality [7, 9–18].
Assessment of alcohol consumption in HIV cohort
studies varies because of the measurement tools imple-
mented, mode of assessment and risk groups under in-
vestigation [18–25]. Most studies have used methods of
alcohol assessment based on brief self-reported ques-
tionnaires relating to quantity and/or frequency of
drinks consumed [26]. Others studies have used patient
interviews, biomarkers or breath tests to assess level of
alcohol consumption [27, 28]. These different measure-
ment tools has led to methodological challenges in
quantifying estimates of alcohol consumption amongst
PLWHIV [29].
In this analysis, we use data routinely collected by
treating physicians in two cohorts of PLWHIV seen for
routine clinical care in Italy, including questions related
to both frequency and quantity of alcohol consumed.
Our objective is two-fold. Firstly, we aim to categorise
drinking behaviour using data routinely collected in our
cohorts by mapping the questions on the electronic case
report form (CRF) to those used in national drinking
guidelines known as the National Institute for Food and
Nutrition (NIFN) in Italy. Secondly, to assess the associ-
ation between alcohol consumption and risk of severe
liver disease (SLD) among PLWHIV with or without
HCV infection.
Methods
Study participants
This analysis includes all PLWHIV (with and without
HCV co-infection) enrolled up to June 2016 in the
ICONA Foundation Study and HepaICONA prospective
cohorts who were free from SLD (see definition in para-
graph below) at study enrolment. Patients enrolled prior
to 1st January 2002 were excluded from this study as al-
cohol assessment in the cohorts was not in standard use
prior to this date. Both cohorts are observational studies
of PLWHIV and details of both cohorts have been pub-
lished elsewhere [30, 31]. In brief, the ICONA Founda-
tion cohort began to enrol PLWHIV in 1997 as long as
they were antiretroviral (ART)-naïve at time of enrol-
ment. Patients’ demographics, clinical and laboratory
data are recorded using an electronic data collection
form. Occurrence of any clinical event, including liver-
related events and causes of death (classified using
CoDe) are recorded [30]. The HepaICONA cohort
began in 2013 and it enrols HIV/HCV co-infected and
HCV viremic individuals who are naive to direct acting
antivirals drugs (DAA) at study entry. Similar data col-
lections processes are implemented as those in place for
the ICONA cohort, including the questions related to al-
cohol consumptions [31]. All patients have given in-
formed consent to participate in the study and ethic
committee approval from all participating centres was
obtained for both cohorts (Additional file 1: Table S1).
Classification of alcohol consumption
Alcohol consumption is collected by physician interview
at study enrolment and at subsequent clinical visits (at
least every 6months) during follow-up. This analysis only
includes assessments carried out at enrolment (baseline),
which for the ICONA cohort is prior to ART initiation.
Exact questions in the patients’ interview (with possible
responses) are as follows; 1) Do you currently drink alco-
hol? (Yes/No/Unknown); 2) How frequently do you drink
alcohol? (Daily/Non-daily/Unknown); 3) How many units
of (Wine/Beer/Spirits) do you consume per day?
Frequency and quantity of units of drink consumed
was translated into drinking categories by mapping the
data to the definitions described in the NIFN guidelines.
A unit of alcohol in Italy is defined as containing 14 g of
pure alcohol which corresponds to 125 ml of wine, 330
ml of a can of beer and 40 ml of liquor [32].
Hazardous drinking is defined as > 3 units/day for men
and for women > 2 units/day. In cases where drinking
was reported as ‘non-daily’ WHO guidelines were used
which state that > 4 drinks per occasion is considered
hazardous drinking [33]. People were classified as mod-
erate drinkers if they consumed an amount below the
hazardous drinking thresholds. Abstainers were people
who reported not drinking alcohol at all.
Alcohol consumption at baseline was categorised into
these three groups described above and an unknown cat-
egory if there was missing data for alcohol consumption
as shown in Fig. 1. In some individuals who reported
more than one type of drink, the drink with the highest
quantity of alcohol was used in the classification process.
In instances were information on alcohol was given in
other metrics e.g. ml, this was converted to units (e.g.
500 ml of wine a day equated to 500 ml/125 ml = 4 units/
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day). In few instances were information reported as hav-
ing a drink with a meal, this was assumed 2 units/day to
take into account of the 2 meals a day.
Definitions of covariates
Demographics were collected at study enrolment. HIV-
related variables (previous AIDS diagnosis, CD4 and
HIV-RNA), hepatitis co-infection (HCV) status and
smoking status were also collected at study enrolment.
HCV status was based on HCVAb+ test or, when the re-
sults for antibody test was not available, using HCV-
RNA > 615 IU/mL or a positive HCV-RNA qualitative
test or evidence of the determination of HCV genotype.
Definition of severe liver disease
Time to the development of severe liver disease in follow-
up was a composite endpoint defined at the time of
experiencing one of the following events (first of these oc-
curring): (i) a FIB4 > 3.25 (where FIB4 was calculated
based on available blood test results using the formula
(age*AST)/PLT*sqrt (ALT) and assessed at each clinical
visit [34];(ii) a clinical diagnosis of liver disease from med-
ical records (ascites, decompensated cirrhosis, hepatocel-
lular carcinoma, hepatic encephalopathy, oesophageal
varices); (iii) liver-related death.
Statistical analyses
Baseline was defined as date of enrolment between 1st
January 2002 and 30th June 2016 in ICONA and be-
tween 1st October 2013 and 30th June 2016 for people
in HepaICONA. Individuals were followed up until the
date of experiencing the composite endpoint or their
follow-up was censored at the date of their clinical visit
at which they were last seen free from SLD. Summary
statistics were used to describe the study participants
overall and after stratification by alcohol consumption
category at baseline. Formal comparisons of categorical
characteristics by groups of alcohol consumption were
performed using chi-squared tests.
Time to SLD was estimated using the Kaplan Meier
method overall and after stratifying by baseline alcohol
consumption category. Univariable and multivariable Cox
regression models were fitted to estimate hazard ratios
(HRs) of the risk of SLD associated with baseline levels of
alcohol consumption. In the Cox regression model, only
time-fixed covariates measured at baseline were included.
Potential confounders measured at baseline were consid-
ered in a series of separate multivariable models fitted
sequentially as follows: Model #1 controlling for demo-
graphic factors (gender, age, nationality, geographical re-
gion, calendar year of enrolment); Model #2 (model #1
plus previous AIDS diagnosis, CD4, HIV-RNA, and HBV
infection status); Model #3 (model #2 plus mode of HIV
transmission, and HCV infection status) and finally model
#4 (model #3 plus smoking status). Results are presented
as adjusted hazard ratios (aHRs) with 95% confidence in-
tervals (95% CI). An interaction term between HCV infec-
tion and alcohol consumption was formally tested to
determine whether the effect of alcohol consumption on
risk of SLD differed by HCV infection status. This could
be done only for the ICONA cohort as HepaICONA in-
cludes only HIV/HCV co-infected individuals. Two differ-
ent methods for handling missing data on alcohol
consumption were applied: (i) people with unknown alco-
hol consumption were included as a separate ‘unknown’
category of the alcohol variable (main analysis); (ii) an
Fig. 1 Alcohol classification based on responses from Physician assessment of alcohol consumption
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analysis in which people with unknown information were
re-classified as ‘Abstainer’, ‘Moderate’ or ‘Hazardous’
drinker using multiple imputation (MI). A Fully Condi-
tional Specification (FCS) imputation algorithm was im-
plemented owing to the discrete nature of the alcohol
consumption variable. We assumed 10 imputes with 100
iterations to be sufficient. Variables considered predictors
of unreported alcohol consumption included in the MI
model were: age, gender, nationality, geographical region,
calendar year enrolled, mode of HIV transmission, AIDS
diagnosis, CD4, HIV-RNA, HCV infection, smoking status
and SLD. Separate univariable and multivariable Cox
models were fitted similar to those used for the main ana-
lysis. Using Rubin’s combination rules, which is a method
that combines estimates from imputed datasets to esti-
mate standard errors, confidence intervals, and p-values to
give an overall estimate of the imputed datasets. All ana-
lyses were performed using SAS (version 9.4, SAS Insti-
tute, Cary North Carolina USA).
Results
Alcohol consumption
We included 9542 patients who satisfied the inclusion
criteria (8876 from ICONA and 666 from HepaICONA).
When mapping our questions to the NIFN guidelines
the distribution according to alcohol consumption was;
abstainers 3422 (36%; 95%CI [35–37]), moderate users
2279 (23%; 95%CI [23–25]), hazardous drinkers 637 (7%;
95%CI [6, 7]), and unknown alcohol status 3204 (34%;
95%CI [33–35]). The distribution according to alcohol
consumption in individuals with available data on alco-
hol consumption (n = 6338) was; abstainers (54%; 95%CI
[53–55]), moderate users (36%; 95%CI [35–37]) and haz-
ardous drinkers (10%; 95%CI [9–11]). After using MI to
reclassify people with missing data, overall distribution
of alcohol consumption was as follows: abstainers (53%),
moderate users (37%) and hazardous drinkers (10%).
Patient characteristics
Table 1 shows baseline characteristics for (n = 6338), over-
all and stratified by alcohol consumption. The majority of
individuals were male (77%); median age [IQR] 38 [31–46]
years. Compared to moderate drinkers, hazardous
drinkers were more likely to be male (p < 0.001), of older
age (p < 0.001), injecting drug users (p < 0.001), smokers
(p < 0.001) and HIV/HCV co-infected (p < 0.001). Com-
pared to individuals with complete data on alcohol con-
sumption, those with missing data were more likely to be
male (p < 0.001), of older age (p < 0.001), to have acquired
HIV through IDU (p < 0.001), to not report smoking sta-
tus (p < 0.001), to have no test result for HCV infection
(p < 0.001) and to be enrolled in later calendar years (p <
0.001) (Additional file 2: Table S2).
Alcohol consumption and risk of severe liver disease
Patients were followed-up for a median [IQR] of 25.2
months [6.1–55.6]. A total of 617 (7%) people experienced
the composite SLD outcome (n = 506 FIB4 > 3.25, n = 110
clinical diagnosis of liver disease, n = 1 liver-related mor-
tality). Fig. 2 shows the Kaplan-Meier estimates of the
time to SLD according to baseline alcohol consumption
level. The estimated cumulative risk of experiencing SLD
by 60months (95% CI) from baseline in abstainers, mod-
erate, hazardous or unknown alcohol consumption were
8.4% (7.1–9.7), 7.9% (6.3–9.5), 10.7% (7.4–14.1) and 11.4%
(9.9–12.9), respectively [log-rank p < 0.001].
In univariable Cox regression analyses with moderate
drinkers as the comparator group, hazardous drinking
and unknown alcohol status were strongly associated
with increased risk of SLD (unadjusted HR = 1.61 [95%
CI: 1.16–2.26]; p = 0.005 and 1.67 [95% CI: 1.34–2.09];
p < 0.001 respectively. In contrast, there was no evidence
for a difference between abstaining and moderate con-
sumption (unadjusted HR = 1.09 [95% CI: 0.87–1.38];
p = 0.446) Table 2. After controlling for age, gender, na-
tionality, region, calendar year enrolled, HIV related fac-
tors and HBV, and still using the moderate consumption
as the comparator, adjusted HR (95%CI) for hazardous
drinking and unknown alcohol consumption were
[aHR = 1.45 (1.03–2.03; p = 0.031) and aHR = 1.37 (1.09–
1.72; p = 0.007)] respectively. However, after additionally
adjusting for mode of HIV transmission and HCV infec-
tion status, the effect of hazardous drinking was attenu-
ated (aHR = 1.30 [95% CI: 0.92–1.82]; p = 0.129) but
unknown alcohol consumption remained associated with
risk of SLD (aHR = 1.43 [95% CI: 1.13–1.80]; p = 0.003).
After further adjustment for smoking status, alcohol
consumption was no longer associated with risk of SLD;
(aHR = 1.09 [95% CI: 0.86–1.38]; global p = 0.446) Table
2. An interaction term between HCV infection and alco-
hol use was not significant, indicating that the associ-
ation between level of alcohol consumption and risk of
SLD did not differ by HCV status (p = 0.740 Fig. 3).
In the univariable Cox regression analyses, after
combining MI estimates from separate multivariable
models, results were similar to those in the main ana-
lysis. Hazardous drinking was associated with the risk
of SLD (unadjusted HR = 1.70 [95% CI: 1.24–2.34]; p =
0.002 and abstaining was not associated with risk SLD
(unadjusted HR = 1.15 [95% CI: 0.90–1.47]; p = 0.261]
Table 2. However, as in the main analysis, after adjust-
ing for potential confounders including mode of HIV
transmission and HCV infection hazardous drinking
was no longer associated with risk of SLD (aHR = 1.29
[95% CI: 0.93–1.78]; p = 0.120). Further adjustment for
smoking status, alcohol consumption was not associ-
ated with risk of SLD (aHR = 1.13 [95%CI: 0.88–1.45];
global p = 0.724) Table 2.
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Table 1 Patients’ characteristics stratified by alcohol consumption classification at baseline
Baseline characteristics Abstainers (N = 3422) Moderate (N = 2279) Hazardous (N = 637) Total (N = 6338)
Gender, n(%)
Male 2363 (69.1%) 1954 (85.7%) 567 (89.0%) 4884 (77.1%)
Female 1059 (30.9%) 325 (14.3%) 70 (11.0%) 1454 (22.9%)
Age, years
Median (IQR) 38 (31, 47) 37 (30, 45) 41 (34, 49) 38 (31, 46)
Mode of HIV Transmission, n(%)
PWID 367 (10.7%) 250 (11.0%) 114 (17.9%) 731 (11.5%)
Homosexual contacts 1317 (38.5%) 1124 (49.3%) 222 (34.9%) 2663 (42.0%)
Heterosexual contacts 1517 (44.3%) 757 (33.2%) 269 (42.2%) 2543 (40.1%)
Other/Unknown 221 (6.5%) 148 (6.5%) 32 (5.0%) 401 (6.3%)
Nationality, n(%)
Italian 2572 (75.2%) 1915 (84.0%) 516 (81.0%) 5003 (78.9%)
Region, n(%)
North 1577 (46.1%) 1144 (50.2%) 382 (60.0%) 3103 (49.0%)
Center 1366 (39.9%) 866 (38.0%) 217 (34.1%) 2449 (38.6%)
South 479 (14.0%) 269 (11.8%) 38 (6.0%) 786 (12.4%)
AIDS diagnosis, n(%)
Yes 336 (9.8%) 156 (6.8%) 43 (6.8%) 535 (8.4%)
CD4 count cells/mm3, n(%)
≤ 300 1156 (33.8%) 580 (25.4%) 172 (27.0%) 1908 (30.1%)
301–500 810 (23.7%) 593 (26.0%) 166 (26.1%) 1569 (24.8%)
≥ 501 1035 (30.2%) 861 (37.8%) 216 (33.9%) 2112 (33.3%)
Unknown 421 (12.3%) 245 (10.8%) 83 (13.0%) 749 (11.8%)
HIV-RNA viral load, n(%)
≤ 5000 605 (17.7%) 389 (17.1%) 114 (17.9%) 1108 (17.5%)
5001–10,000 208 (6.1%) 172 (7.5%) 48 (7.5%) 428 (6.8%)
10,001–100,000 1222 (35.7%) 922 (40.5%) 231 (36.3%) 2375 (37.5%)
≥ 100,001 1025 (30.0%) 567 (24.9%) 179 (28.1%) 1771 (27.9%)
Unknown 362 (10.6%) 229 (10.0%) 65 (10.2%) 656 (10.4%)
Smoking, n(%)
No 2201 (64.3%) 924 (40.5%) 188 (29.5%) 3313 (52.3%)
Yes 1092 (31.9%) 1268 (55.6%) 413 (64.8%) 2773 (43.8%)
Unknown 129 (3.8%) 87 (3.8%) 36 (5.7%) 252 (4.0%)
Hepatitis B, n(%)
Yes 107 (3.1%) 59 (2.6%) 25 (3.9%) 191 (3.0%)
HCV Infection, n(%)
Negative 2366 (69.1%) 1549 (68.0%) 409 (64.2%) 4324 (68.2%)
Positive 410 (12.0%) 250 (11.0%) 119 (18.7%) 779 (12.3%)
Not tested 646 (18.9%) 480 (21.1%) 109 (17.1%) 1235 (19.5%)
Calendar year, n(%)
2002–2006 473 (13.8%) 313 (13.7%) 69 (10.8%) 855 (13.5%)
2007–2012 1113 (32.5%) 671 (29.4%) 218 (34.2%) 2002 (31.6%)
2013–2016 1836 (53.7%) 1295 (56.8%) 350 (54.9%) 3481 (54.9%)
Follow-up (months)
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Discussion
One of the objectives of this analysis was to classify drink-
ing behaviour using data on alcohol consumption rou-
tinely collected through physician assessment in our
cohorts of PLWHIV seen for routine care in Italy. In this
analysis involving 9542 PLWHIV, using the NIFN guide-
lines of whom 6338 (66%) had data on alcohol consump-
tion. In our study population, 10% of individuals were
classified as hazardous drinkers, 36% as moderate drinkers
and 54% as abstainers. The overall estimate of the current
prevalence of alcohol consumption was 46%. Other HIV
studies in which alcohol consumption was measured with
similar questionnaires have reported prevalence of current
use ranging between [27–95%] [18, 21–25]. Our estimate
of hazardous use of 10% was similar to reported estimates
in other studies ranging from [8–12%] [5, 16, 18, 23, 35].
Other studies using different assessment tools reported
higher estimates of alcohol consumption. For example,
Samet J et al assessed alcohol consumption in HIV posi-
tive individuals in USA by means of patient’s interviews
using a series of questions on quantity and frequency and
also carried out breath alcohol level test [1]. These authors
reported 27% with moderate drinking behaviour and 16%
with risky drinking. In addition the use of different meas-
urement tools is a further reason to explain lower preva-
lence of hazardous drinking in our study could be due to
collection of alcohol consumption via face to face rather
than anonymously.
Thirty four percent of individuals in this analysis had
missing data on alcohol consumption. This large propor-
tion of missing data highlights the challenges of collecting
complete data on alcohol consumption in observational
studies of PLWHIV. It is also unclear whether unreported
alcohol consumption may have arisen from questions not
being asked by the physician or the participant being un-
willing to give information for other unknown reasons.
The prevalence of people with missing information was
generally consistent with that seen in other HIV studies
showing estimates of under-reporting ranging between
[7–41%] [8, 25, 36, 37]. Possible reasons for under-
reporting of alcohol use include social desirability and
fear of the impact on antiretroviral therapy initiation
[27, 35, 36]. Of note, it is part of the Italian culture to
assume that a drink with a meal is normal consumption
which might also explain the under-reporting. Some
studies have assessed the extent of under-reporting by
comparing self-reported alcohol consumption with
blood tests or biomarkers, or interviews carried out by
professionals and found a lack of agreement between
these measures [27, 36, 38]. Physician interview like
ours are likely to measure alcohol consumption even less
accurately than self-administered questionnaires [29].
Table 1 Patients’ characteristics stratified by alcohol consumption classification at baseline (Continued)
Baseline characteristics Abstainers (N = 3422) Moderate (N = 2279) Hazardous (N = 637) Total (N = 6338)
Median (IQR) 26.5 (7.4, 57.1) 23.4 (4.8, 53.5) 25.6 (5.6, 54.8) 25.2 (6.1, 55.6)
Fig. 2 Kaplan Meier estimate of the risk of severe liver disease stratified by alcohol consumption classification
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Different classifications of alcohol consumption were
used across studies making it difficult to make valid
comparisons. It has to be noted that most of other pub-
lished studies were enriched with people in specific risk
groups who are more likely to have alcohol problems
[8, 36, 39]. In contrast, our estimates are from a hetero-
geneous cohort with 12% PWID, 42% MSMs and 40%
who acquired HIV through heterosexual contacts. In-
deed, we did find that PWID were more likely to have
missing data for alcohol consumption which in turn
was associated with higher risk of SLD.
This analysis also set out to investigate whether our
measure of alcohol consumption was useful to predict the
risk of SLD. Seven percent of our study population experi-
enced SLD over follow-up. Although the risk of SLD ap-
peared marginally lower for moderate drinkers compared
with abstainers, this was not statistically significant. A
lower risk in moderate drinkers compared to abstainers
has been previously documented and a possible explan-
ation could be due to the fact that patients who are cur-
rently abstaining may include individuals who were never
drinkers as well as those who previously drank and had to
abstain due to medical reasons or other reasons [40]. In
our study it was not possibly to separate these groups. We
found an association of hazardous drinking with increased
risk of SLD that was largely independent of baseline
demographic and HIV related factors and HBV. However,
after further adjusting for mode of HIV transmission,
HCV infection and smoking status the association was
largely attenuated. Lim JK et al, in 2111 PLWHIV also
found a moderate increased risk of advanced fibrosis in
people with hazardous alcohol consumption (aOR = 1.26
(95%CI: 0.87–1.82) compared to non-hazardous drinkers)
after adjusting for a number of potential confounders in-
cluding HCV infection [11]. In another study including
308 PLWHIV, in which heavy alcohol consumption was
defined as > 2 drinks/day or ≥ 5 drinks per occasion and >
1 drink per day or ≥ 4 drinks per occasion for men and
women respectively, reported that 10% of the study popu-
lation developed of liver fibrosis. Consistent with our re-
sults, the authors found a moderate difference in risk
according to alcohol consumption and no significant asso-
ciation between heavy alcohol consumption and risk of
advanced liver fibrosis (aOR = 1.14 [95%CI: 0.47–2.77]
compared to non-heavy alcohol consumption; p = 0.77)
[41]. In contrast, Chaudhry et al. 2009 did find an associ-
ation between alcohol consumption and liver fibrosis mea-
sured using the APRI score after adjusting for potential
confounders including HCV infection[aRR = 2.30 (95%CI:
1.26–4.17)]. Of interest, also in their analysis there was no
evidence that the association between alcohol consump-
tion and the risk of SLD varied by HCV infection status.
Our study has several other limitations that should be
addressed. First, we used a time-fixed covariate at enrol-
ment to classify individuals’ drinking behaviour for the
study period, although it is possible that drinking habits
changed over follow-up potentially leading to a dilution
of the association. This was done mainly to simplify the
analysis as mechanisms of time-dependent confounding
in this context are largely unexplored and potentially dif-
ficult to address by means of a standard Cox regression
analysis. Secondly, as typical in the observational setting,
we have to assume that results cannot be explained by
residual or unmeasured confounding. In addition, be-
cause of the large proportion of people with missing
data, selection bias cannot be entirely ruled out. People
Fig. 3 Cox regression adjusted HRs stratified by HCV status for risk of severe liver disease
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lacking information on alcohol were indeed different
from those with complete data for a number of factors
known to be associated with the risk of SLD (Additional
file 2: Table S2). However, use of multiple imputation
gave similar results to the main analysis and the amount
of missing data observed in out cohorts is consistent
with other HIV cohorts collecting data on alcohol use.
Thirdly, data collected on mode of HIV transmission in
ICONA and HepaICONA is not able to distinguish be-
tween ex-PWID and current PWID, leading to potential
residual confounding due to misclassification. Finally, it’s
possible that the physicians may not ask the questions
on alcohol use in standardised fashion in accordance
with the format on the eCRF.
Conclusion
In conclusion, we evaluated the value of information on
alcohol consumption obtained by brief physician interview
of PLWHIV to predict their future risk of occurrence of
SLD. We found an association between alcohol consump-
tion and risk of SLD which was however partly explained
by differences in HCV status, HIV mode of transmision
and smoking. There was no evidence that the association
was stronger when restricting the analysis to the HCV-
infected population. It is conceivable that the weak associ-
ation found is due to misclassification of the exposure, so
efforts should be made in order to collect more accurate
information on alcohol consumption in cohorts of HIV/
HCV infected individuals. In particular data collection on
historical alcohol consumption including items which
could allow to distinguish between people who had cur-
rently stopped drinking from those who never drank
would be useful for future studies.
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